<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01156779</url>
  </required_header>
  <id_info>
    <org_study_id>DA3091_DM_I</org_study_id>
    <nct_id>NCT01156779</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects</brief_title>
  <acronym>SR-Exenatide</acronym>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating, Phase I Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of DA-3091 After Subcutaneous Injection in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I clinical study is to evaluate the safety and tolerance of DA-3091 and to
      characterize the pharmacokinetic/pharmacodynamic of DA-3091 in healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I dose escalation study. To meet the clinical objectives, we are using a
      two-part approach. In part I, 4 subjects are injected 0.5mg dose of DA-3091 or
      placebo(Single/Subcutaneous Injection). After completion of part I study, we are reporting
      data about safety to IDMC. In part II, 8 subjects per group are injected 1mg, 2mg, 4mg of
      DA-3091 or placebo through dose escalating protocol. The ratio of DA-3091 and placebo is 3:1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety</measure>
    <time_frame>84 days</time_frame>
    <description>Adverse Events
Laboratory Results
Vital sign, Physical Examination, EKG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics</measure>
    <time_frame>PK : 84 days / PD : 42days</time_frame>
    <description>PK : Cmax, Tmax, AUClast PD : Glucose, Insulin, Glucagon, C-peptide in blood sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DA-3091</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SR-exenatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of DA-3091</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-exenatide</intervention_name>
    <description>Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection</description>
    <arm_group_label>DA-3091</arm_group_label>
    <arm_group_label>Placebo of DA-3091</arm_group_label>
    <other_name>DA-3091</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age : 20 ~ 45 years old

          2. Healthy Male

          3. Body weight : ≥50kg and Ideal body weight ± 20%

          4. Informed consent

        Exclusion Criteria:

          1. Clinically significant medical history

          2. Acute or Chronic pancreatitis

          3. Clinically significant hypersensitivity of Drugs

          4. Clinically significant cutaneous disorder

          5. History of administration of exenatide

          6. Disorder of blood pressure

          7. History of drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D., Ph.d</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial center, Clinical Research institute, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2010</study_first_submitted>
  <study_first_submitted_qc>July 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2010</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SR-Exenatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

